"10.1371_journal.pone.0080513","plos one","2013-11-15T00:00:00Z","Donald M Lyall; Natalie A Royle; Sarah E Harris; Mark E Bastin; Susana Muñoz Maniega; Catherine Murray; Michael W Lutz; Ann M Saunders; Allen D Roses; Maria C del Valdés Hernández; John M Starr; David J Porteous; Joanna M Wardlaw; Ian J Deary","Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, United Kingdom; Brain Research Imaging Centre, Division of Neuroimaging Sciences, University of Edinburgh, Edinburgh, United Kingdom; Department of Psychology, University of Edinburgh, Edinburgh, United Kingdom; Medical Genetics Section, Centre for Genomics and Experimental Medicine and MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Scottish Imaging Network, A Platform for Scientific Excellence (SINAPSE) Collaboration, Division of Neuroimaging Sciences, University of Edinburgh, Edinburgh, United Kingdom; Joseph & Kathleen Bryan Alzheimers Disease Research Center, Department of Neurology, Duke University Medical Center, Durham, North Carolina, United States of America; Zinfandel Pharmaceuticals, Inc., Durham, North Carolina, United States of America; Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, United Kingdom","Conceived and designed the experiments: DML JMW DJP IJD. Performed the experiments: DML. Analyzed the data: DML. Wrote the manuscript: DML. Interpretation of the results, revised the article critically for important intellectual content, and approved the final version to be published: DML NAR SEH MEB SMM CM MWL AMS ADR MVH JMS DJP JMW IJD.","ADR is the CEO and only stock holder of Zinfandel Pharmaceuticals, a company in an Alliance with Takeda Pharmaceuticals, to perform the prospective qualification of the TOMM40 marker for age of onset distribution of Alzheimers Disease.  For this study, Zinfandel Pharmaceuticals paid for the TOMM40 assays to be performed for medical research, not as a clinical diagnostic.  AMS is the spouse of ADR, and AMS and WML are consultants to Zinfandel Pharmaceuticals.  This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","11","Donald M Lyall","DML",14,TRUE,4,1,1,1,TRUE,TRUE,FALSE,0,NA,FALSE
